Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study.

dynamic contrast-enhanced MRI histological response neoadjuvant chemotherapy osteosarcoma response monitoring survival outcome

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 May 2024
Historique:
received: 02 05 2024
revised: 17 05 2024
accepted: 18 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

The decreased perfusion of osteosarcoma in dynamic contrast-enhanced (DCE) MRI, reflecting a good histological response to neoadjuvant chemotherapy, has been described. In this study, we aim to explore the potential of the relative wash-in rate as a prognostic factor for event-free survival (EFS). Skeletal high-grade osteosarcoma patients, treated in two tertiary referral centers between 2005 and 2022, were retrospectively included. The relative wash-in rate (rWIR) was determined with DCE-MRI before, after, or during the second cycle of chemotherapy (pre-resection). A previously determined cut-off was used to categorize patients, where rWIR < 2.3 was considered poor and rWIR ≥ 2.3 a good radiological response. EFS was defined as the time from resection to the first event: local recurrence, new metastases, or tumor-related death. EFS was estimated using Kaplan-Meier's methodology. Multivariate Cox proportional hazard model was used to estimate the effect of histological response and rWIR on EFS, adjusted for traditional prognostic factors. Eighty-two patients (median age: 17 years; IQR: 14-28) were included. The median follow-up duration was 11.8 years (95% CI: 11.0-12.7). During follow-up, 33 events occurred. Poor histological response was not significantly associated with EFS (HR: 1.8; 95% CI: 0.9-3.8), whereas a poor radiological response was associated with a worse EFS (HR: 2.4; 95% CI: 1.1-5.0). In a subpopulation without initial metastases, the binary assessment of rWIR approached statistical significance (HR: 2.3; 95% CI: 1.0-5.2), whereas its continuous evaluation demonstrated a significant association between higher rWIR and improved EFS (HR: 0.7; 95% CI: 0.5-0.9), underlining the effect of response to chemotherapy. The 2- and 5-year EFS for patients with a rWIR ≥ 2.3 were 85% and 75% versus 55% and 50% for patients with a rWIR < 2.3. The predicted poor chemo response with MRI (rWIR < 2.3) is associated with shorter EFS even when adjusted for known clinical covariates and shows similar results to histological response evaluation. rWIR is a potential tool for future response-based individualized healthcare in osteosarcoma patients before surgical resection.

Sections du résumé

BACKGROUND BACKGROUND
The decreased perfusion of osteosarcoma in dynamic contrast-enhanced (DCE) MRI, reflecting a good histological response to neoadjuvant chemotherapy, has been described.
PURPOSE OBJECTIVE
In this study, we aim to explore the potential of the relative wash-in rate as a prognostic factor for event-free survival (EFS).
METHODS METHODS
Skeletal high-grade osteosarcoma patients, treated in two tertiary referral centers between 2005 and 2022, were retrospectively included. The relative wash-in rate (rWIR) was determined with DCE-MRI before, after, or during the second cycle of chemotherapy (pre-resection). A previously determined cut-off was used to categorize patients, where rWIR < 2.3 was considered poor and rWIR ≥ 2.3 a good radiological response. EFS was defined as the time from resection to the first event: local recurrence, new metastases, or tumor-related death. EFS was estimated using Kaplan-Meier's methodology. Multivariate Cox proportional hazard model was used to estimate the effect of histological response and rWIR on EFS, adjusted for traditional prognostic factors.
RESULTS RESULTS
Eighty-two patients (median age: 17 years; IQR: 14-28) were included. The median follow-up duration was 11.8 years (95% CI: 11.0-12.7). During follow-up, 33 events occurred. Poor histological response was not significantly associated with EFS (HR: 1.8; 95% CI: 0.9-3.8), whereas a poor radiological response was associated with a worse EFS (HR: 2.4; 95% CI: 1.1-5.0). In a subpopulation without initial metastases, the binary assessment of rWIR approached statistical significance (HR: 2.3; 95% CI: 1.0-5.2), whereas its continuous evaluation demonstrated a significant association between higher rWIR and improved EFS (HR: 0.7; 95% CI: 0.5-0.9), underlining the effect of response to chemotherapy. The 2- and 5-year EFS for patients with a rWIR ≥ 2.3 were 85% and 75% versus 55% and 50% for patients with a rWIR < 2.3.
CONCLUSION CONCLUSIONS
The predicted poor chemo response with MRI (rWIR < 2.3) is associated with shorter EFS even when adjusted for known clinical covariates and shows similar results to histological response evaluation. rWIR is a potential tool for future response-based individualized healthcare in osteosarcoma patients before surgical resection.

Identifiants

pubmed: 38893075
pii: cancers16111954
doi: 10.3390/cancers16111954
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Gijsbert M Kalisvaart (GM)

Department of Radiology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Richard E Evenhuis (RE)

Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, The Netherlands.

Willem Grootjans (W)

Department of Radiology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Thomas Van Den Berghe (T)

Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium.

Martijn Callens (M)

Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium.

Judith V M G Bovée (JVMG)

Department of Pathology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

David Creytens (D)

Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium.

Hans Gelderblom (H)

Department of Medical Oncology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Frank M Speetjens (FM)

Department of Medical Oncology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Lore Lapeire (L)

Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.

Gwen Sys (G)

Department of Orthopedic Surgery and Traumatology, Ghent University Hospital, 9000 Ghent, Belgium.

Marta Fiocco (M)

Department of Biomedical Science, Section Medical Statistics, Leiden University Medical Center, 2333 Leiden, The Netherlands.
Center for Pediatric Oncology, Princess Maxima Center, 3584 Utrecht, The Netherlands.
Mathematical Institute, Leiden University, 2300 Leiden, The Netherlands.

Koenraad L Verstraete (KL)

Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium.

Michiel A J van de Sande (MAJ)

Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, The Netherlands.
Center for Pediatric Oncology, Princess Maxima Center, 3584 Utrecht, The Netherlands.

Johan L Bloem (JL)

Department of Radiology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Classifications MeSH